Malignant hematopathy
Conditions
Interventions
Experimental group:Ruxolitinib+CSA+MTX+MMF
Control group:CSA+MTX+MMF
Sponsors
The Second Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients with acute leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, chronic myeloid leukemia and lymphoma diagnosed according to the WHO classification criteria for hematopoietic and lymphoid tissue tumors in 2017; patients with aplastic anemia diagnosed according to the Chinese Expert Consensus on Diagnosis and Treatment of Aplastic Anemia (2017 edition) Patients with obstructive anemia. The indications for transplantation refer to the consensus of Chinese experts on allogeneic hematopoietic stem cell transplantation for the treatment of hematological diseases (2014 edition); 2. recipients of allogeneic hematopoietic stem cell transplantation (including HLA-compatible or incomplete-compatible allogeneic stem cell transplantation and unrelated donor transplantation); 3. male or female aged 15-65 years; 4. ECOG score 0-2; 5. Informed consent must be signed before the start of the research procedure. Informed consent should be signed by the patient himself or his immediate relatives aged 18 years or over. Informed consent should be signed by legal guardians for adolescents under 18 years of age.
Exclusion criteria
Exclusion criteria: 1. received hematopoietic stem cell transplantation within the past 1 year; 2. Patients who had developed GVHD before enrollment 3. uncontrolled active infections, including significant bacterial, fungal, viral or parasitic infections requiring treatment; 4. evidence of active viral infection (confirmed by peripheral blood viral load measurement), including CMV, EBV, HBV or HCV, HIV; 5. evidence of active TB; 6. severe respiratory diseases; 7. mental disorders can not meet the requirements of research, treatment and monitoring; 8. pregnant patients or patients who cannot take appropriate contraceptive measures during treatment 9. anaphylaxis to any of the components of Ruxolitinib is known; 10. severe renal impairment, defined as serum creatinine > 2 mg/dL; 11. clinically significant or uncontrolled heart disease; 12. cholestatic disease, or unrelieved hepatic sinus obstruction syndrome/hepatic vein occlusion; 13. the researcher thinks that is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence of aGVHD;the incidence of virus reaction;neutral and platelet implantation time; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;RR;TRM;the incidence of cGVHD;Ruxolitinib side effect; | — |
Countries
China
Contacts
Public ContactFu-xu Wang
the Second Hospital of Hebei Medical University
Outcome results
None listed